Health Canada
www.hc-sc.gc.ca
Home
> Drugs & Health Products
> Public Involvement & Consultations
> Veterinary Drugs
Institutional links
-
Back to
-
Explore...
-
Transparency
Consultations
Current Consultations
Past Consultations
- Consultation on VICH guideline 51: statistical evaluation of stability data (step 4)
- Consultation - Maximum residue limit (MRL) proposal for Amprolium, Bacitracin, Cloxacillin, Dichlorvos, Erythromycin, Gamithromycin, Meloxicam, Novobiocin, Penicillin G, and Toltrazuril
- Consultation on revised VICH guideline 36: Studies to evaluate the safety of residues of veterinary drugs in human food: general approach to establish a microbiological acceptable daily intake (ADI) (step 4)
- Consultation on VICH guideline 35: Pharmacovigilance of Veterinary Medicinal Products: Electronic Standards for Transfer of Data (step 4)
- Consultation on VICH revised guideline 18: Quality-Impurities: Residual solvents in New Veterinary Medicinal Products, Active Substances and Excipients (step 4)
- Consultation on VICH guideline 46: Studies to evaluate the Metabolism and Residue Kinetics of Veterinary Drugs in Food-producing Animals: Metabolism Study to determine the Quantity and Identify the Nature of Residues (step 4).
- Consultation on VICH guideline 47: Studies to evaluate the metabolism and residue kinetics of veterinary drugs in food-producing animals: Comparative metabolism studies in laboratory animals (step 4)
- Consultation on VICH guideline 48: Studies to evaluate the Metabolism and Residue Kinetics of Veterinary Drugs in Food-producing Animals: Marker Residue Depletion Studies to establish Product Withdrawal Periods (step 4)
- Consultation on VICH guideline 49: Guidelines for the Validation of Analytical Methods used in Residue Depletion Studies (step 4)
- Consultation - Maximum residue limit (MRL) proposal for Amoxicillin, Neomycin, Ormetoprim, Tetracycline, Chlortetracycline, Oxytetracycline, Tilmicosin, Tricaine Methanesulfonate, Tulathromycin and Zoalene
- Food and Drug Regulations - Project Number 1621 - Schedule F Amendment
- Consultation - Maximum residue limit (MRL) proposal for Albendazole, Fenbendazole, Flunixin, Zilpaterol, Doramectin, Emamectin, Ivermectin, Moxidectin, Streptomycin, Dihydrostreptomycin and Gentamicin sulphate